Harrow Health, Inc. (NASDAQ:HROW - Get Free Report) major shareholder Opaleye Management Inc. bought 20,000 shares of Harrow Health stock in a transaction dated Thursday, April 25th. The stock was acquired at an average price of $9.97 per share, with a total value of $199,400.00. Following the acquisition, the insider now directly owns 3,815,000 shares of the company's stock, valued at $38,035,550. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Large shareholders that own more than 10% of a company's shares are required to disclose their sales and purchases with the SEC.
Opaleye Management Inc. also recently made the following trade(s):
- On Tuesday, April 23rd, Opaleye Management Inc. bought 11,715 shares of Harrow Health stock. The stock was acquired at an average price of $10.29 per share, with a total value of $120,547.35.
- On Friday, April 19th, Opaleye Management Inc. acquired 29,400 shares of Harrow Health stock. The shares were purchased at an average price of $10.56 per share, with a total value of $310,464.00.
- On Thursday, March 28th, Opaleye Management Inc. acquired 50,000 shares of Harrow Health stock. The shares were purchased at an average price of $12.82 per share, with a total value of $641,000.00.
- On Wednesday, March 20th, Opaleye Management Inc. acquired 50,600 shares of Harrow Health stock. The shares were purchased at an average price of $9.65 per share, with a total value of $488,290.00.
Harrow Health Price Performance
Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years
From Banyan Hill Publishing | Ad
If you think AI is big, then you have got to check out something I call Imperium…
By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)
Watch my video for all of the details
NASDAQ HROW opened at $10.00 on Friday. Harrow Health, Inc. has a fifty-two week low of $7.60 and a fifty-two week high of $28.25. The stock's 50-day moving average is $11.53 and its two-hundred day moving average is $11.25. The company has a debt-to-equity ratio of 2.60, a quick ratio of 2.61 and a current ratio of 2.83.
Harrow Health (NASDAQ:HROW - Get Free Report) last posted its earnings results on Tuesday, March 19th. The company reported ($0.27) earnings per share for the quarter. Harrow Health had a negative net margin of 18.75% and a negative return on equity of 29.48%. The company had revenue of $36.36 million for the quarter, compared to the consensus estimate of $37.65 million. Equities research analysts anticipate that Harrow Health, Inc. will post -0.39 EPS for the current year.
Wall Street Analysts Forecast Growth
HROW has been the subject of several recent research reports. Craig Hallum initiated coverage on Harrow Health in a report on Thursday, April 11th. They set a "buy" rating and a $24.00 price objective for the company. B. Riley cut their price objective on Harrow Health from $30.00 to $26.00 and set a "buy" rating for the company in a report on Friday, March 22nd.
Check Out Our Latest Stock Report on Harrow Health
Hedge Funds Weigh In On Harrow Health
Institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in Harrow Health during the third quarter valued at about $26,000. Stonehage Fleming Financial Services Holdings Ltd acquired a new stake in shares of Harrow Health in the third quarter valued at about $34,000. China Universal Asset Management Co. Ltd. grew its position in shares of Harrow Health by 347.5% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company's stock valued at $46,000 after purchasing an additional 3,155 shares during the last quarter. Tower Research Capital LLC TRC grew its position in shares of Harrow Health by 122.2% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,073 shares of the company's stock valued at $90,000 after purchasing an additional 4,440 shares during the last quarter. Finally, Drive Wealth Management LLC acquired a new stake in shares of Harrow Health in the first quarter valued at about $240,000. 72.76% of the stock is currently owned by institutional investors.
About Harrow Health
(
Get Free Report)
Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
